Find disease awareness content and relevant supporting materials

Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...

Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that ...

The introduction of BRAF and MEK inhibitors into clinical practice improved the prognosis of metastatic melanoma patients. The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown...

Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies. Since 2011, four new classes of medications...

Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.

Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma.

We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.

Detection and removal of melanoma, before it has metastasized, dramatically improves prognosis and survival.

This ASCO guideline update reviews systemic therapy for melanoma, adding new recommendations for neoadjuvant pembrolizumab, adjuvant nivolumab or pembrolizumab, and combination regimens for advanced disease. It also removes outdated options like talimogene laherparepvec.

The SEOM-GEM guidelines address the rising incidence of cutaneous melanoma and emphasize early diagnosis and timely treatment. They provide evidence-based recommendations for adjuvant and neoadjuvant therapies, advanced disease management, and follow-up strategies, including special cases like brain metastases.